First-line ICIs in renal cell carcinoma
Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-α) and high-dose interleukin−2 (HD IL−2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of...
Main Authors: | Vincenzo Fiorentino, Pietro Tralongo, Luigi Maria Larocca, Cristina Pizzimenti, Maurizio Martini, Francesco Pierconti |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-08-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2023.2225386 |
Similar Items
-
Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples
by: Vincenzo Fiorentino, et al.
Published: (2023-08-01) -
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma
by: Alessandro Samuelly, et al.
Published: (2024-01-01) -
DOG1 as an Immunohistochemical Marker of Acinic Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Vincenzo Fiorentino, et al.
Published: (2022-08-01) -
Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
by: Zeynep Akbulut, et al.
Published: (2024-04-01) -
Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition
by: J. H. Börner, et al.
Published: (2023-09-01)